6-sulfonamidoquinazoline-2,4-dione | 954272-54-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-sulfonamidoquinazoline-2,4-dione
• 英文别名: 2,4-Dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide；2,4-dioxo-1H-quinazoline-6-sulfonamide
• CAS: 954272-54-9
• 化学式: C₈H₇N₃O₄S
• mdl: MFCD09737124
• 分子量: 241.227
• InChiKey: KAWUVVGXVHQMKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  127
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,4-二羰基-1,2,3,4-四氢喹唑啉-6-磺酰氯 在 氨 作用下， 反应 2.0h， 以86%的产率得到6-sulfonamidoquinazoline-2,4-dione
  参考文献：
  名称：

  Quinazolines 1. Synthesis and chemical reactions of 6-chlorosulfonyl-quinazoline-2,4-diones

  摘要：

  Treatment of quinazoline-2,4-dione and its symmetrical 1,3-dialkyl derivatives with chlorosulfonic acid gave the corresponding 6-chlorosulfonylquinazoline-2,4-diones. Reaction of the compounds obtained with nucleophilic agents (water, ammonia, aliphatic and cyclic amines) gave the corresponding free 2,4-dioxoquinazoline-6-sulfonic acids, 6-sulfamidoquinazoline-2,4-diones, and 2,4-dioxoquinazoline-6-sulfonic acid amides.

  DOI：

  10.1007/s10593-008-0048-y

文献信息

• [EN] 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG<br/>[FR] DÉRIVÉS DE 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE EN TANT QU'INHIBITEURS DE LA PARG
  申请人：CANCER REC TECH LTD

  公开号：WO2016092326A1

  公开（公告）日：2016-06-16

  The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

  本发明涉及作为PARG（Poly ADP-ribose glycohydrolase）酶活性抑制剂的I式化合物，其中R1a、R1b、R1c、R1d、R1e、W、X1、X2、X3、X4、X5、X6、X7、c如本文所定义。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及PARG活性的疾病或症状中的用途。
• [EN] QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS<br/>[FR] DÉRIVÉS DE QUINAZOLINONE EN TANT QU'AGENTS ANTIVIRAUX
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2012087938A1

  公开（公告）日：2012-06-28

  Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供了化合物及其药用盐，它们的药物组合物，它们的制备方法，以及它们用于治疗由黄病毒科（Flaviviridae）家族成员介导的病毒感染，如丙型肝炎病毒（HCV）的用途。
• [EN] HETEROCYCLIC SULFONAMIDES AS INHIBITORS OF TRANSFER RNA SYNTHETASE FOR USE AS ANTIBACTERIAL AGENTS<br/>[FR] SULFAMIDES HÉTÉROCYCLIQUES SERVANT D'INHIBITEURS DE SYNTHÉTASE D'ARN DE TRANSFERT, DESTINÉS À ÊTRE UTILISÉS EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2012014109A1

  公开（公告）日：2012-02-02

  The present invention provides aromatic sulphonamides as tRNA synthetase inhibitors and process for their synthesis, pharmaceutical composition and method for treatment. Compounds disclosed can be used as antibacterial agents for the treatment or prevention of conditions caused by or contributed by aerobic and anaerobic Gram-positive pathogens, more particularly against bacterium, for example Staphylococcus, Enterococci and Streptococci. Compounds disclosed are used in particular for the treatment of skin and soft tissue infection, Formula (I).

  本发明提供了芳香磺胺类化合物作为tRNA合成酶抑制剂，以及它们的合成方法、药物组合物和治疗方法。所披露的化合物可用作抗菌剂，用于治疗或预防由厌氧和厌氧革兰氏阳性病原体引起或促成的疾病，特别是对抗细菌，例如葡萄球菌、肠球菌和链球菌。所披露的化合物特别用于治疗皮肤和软组织感染，化学式(I)。
• 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US10239843B2

  公开（公告）日：2019-03-26

  The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

  本发明涉及作为 PARG（聚 ADP-核糖糖水解酶）酶活性抑制剂的式 I 化合物，其中 R1a、R1b、R1c、R1d、R1e、W、X1、X2、X3、X4、X5、X6、X7、c 各如本文所定义。本发明还涉及制备这些化合物的工艺、包含这些化合物的药物组合物，以及它们在治疗增殖性疾病（如癌症）和其他涉及 PARG 活性的疾病或病症中的用途。
• 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG
  申请人：Cancer Research Technology Ltd

  公开号：EP3230273A1

  公开（公告）日：2017-10-18